Who Paid My Doc
Jennifer Hunn
Clinical Nurse Specialist, Family Health Saint Peters, MO Nurse Practitioner
NPI 1497101133 CMS profile 10419799
201 Bjc Saint Peters Dr, Suite 100, Saint Peters, MO 63376
General payments
$5,375
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Jennifer Hunn of Saint Peters, MO is reported in the CMS Open Payments database as having received $5,375 across 354 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 93rd percentile of Clinical Nurse Specialist, Family Health profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,065 | 50 | |
| 2024 | General | $1,108 | 62 | |
| 2023 | General | $1,200 | 89 | |
| 2022 | General | $1,064 | 87 | |
| 2021 | General | $938 | 66 |
Beside peers
- Jennifer Hunn
- Clinical Nurse Specialist, Family Health median
- Middle half of Clinical Nurse Specialist, Family Health
- National median
In program year 2025, general payments to Jennifer Hunn were reported at $1,065. Among 164 Clinical Nurse Specialist, Family Health profiles paid that year, the median was $216 and the middle half received between $57 and $492.
Show as a table
| Year | Jennifer Hunn | Clinical Nurse Specialist, Family Health median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | — | — | $163 |
| 2020 | $0 | — | — | $114 |
| 2021 | $938 | $151 | $46–$400 | $132 |
| 2022 | $1,064 | $153 | $37–$527 | $149 |
| 2023 | $1,200 | $139 | $50–$451 | $160 |
| 2024 | $1,108 | $150 | $46–$571 | $164 |
| 2025 | $1,065 | $216 | $57–$492 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 130 drugsPart D claims
5,781
Drug cost
$496,307
Branded share of claims
20%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ozempic Semaglutide | Brand | 71 | $80,403 | |
| Eliquis Apixaban | Brand | 40 | $43,194 | |
| Mounjaro Tirzepatide | Brand | 40 | $42,020 | |
| Tresiba Flextouch U-100 Insulin Degludec | Brand | 58 | $40,160 | |
| Myrbetriq Mirabegron | Brand | 39 | $25,299 | |
| Farxiga Dapagliflozin Propanediol | Brand | 23 | $22,222 | |
| Spiriva Respimat Tiotropium Bromide | Brand | 33 | $21,817 | |
| Vraylar Cariprazine Hcl | Brand | 13 | $21,341 | |
| Linzess Linaclotide | Brand | 31 | $19,891 | |
| Xarelto Rivaroxaban | Brand | 35 | $19,755 |
The 10 drugs with the highest cost, of 130 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,644 Part D prescribers listed as Certified Clinical Nurse Specialist; they describe a distribution and say nothing about conduct.
Payments and prescribing
First 5 of 31 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| VRAYLAR |
|
$81 | 13 | — |
| REXULTI |
|
$79 | — | — |
| UBRELVY |
|
$74 | — | — |
| Ozempic |
|
$73 | 71 | — |
| QULIPTA |
|
$61 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See more in the dashboard: 25 with a free account, all 31 with PatronRecords
354 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Clinical Nurse Specialist, Family Health in Missouri
Andrew Garner
Clinical Nurse Specialist, Family Health · Cape Girardeau, MO
Jessica Bell
Clinical Nurse Specialist, Family Health · Cuba, MO
Heather Cheaney
Clinical Nurse Specialist, Family Health · Farmington, MO
Susan Vogelsmeier
Clinical Nurse Specialist, Family Health · Marshall, MO
Bernita Bell
Clinical Nurse Specialist, Family Health · Cape Girardeau, MO
Jana Graber
Clinical Nurse Specialist, Family Health · Kansas City, MO
Related records
Clinical Nurse Specialist, Family Health in Missouri
Practitioners in the same specialty and state, ranked by reported value.
All Clinical Nurse Specialist, Family Health
Everyone recorded under this specialty, nationwide.
Doctors in Missouri
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.